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Human cytomegalovirus (HCMV) is an important
pathogen with multiple immune evasion strategies,
including virally facilitated degradation of host anti-
viral restriction factors. Here, we describe a multi-
plexed approach to discover proteins with innate
immune function on the basis of active degradation
by the proteasome or lysosome during early-phase
HCMV infection. Using three orthogonal proteomic/
transcriptomic screens to quantify protein degrada-
tion, with high confidence we identified 35 proteins
enriched in antiviral restriction factors. A final screen
employed a comprehensive panel of viral mutants to
predict viral genes that target >250 human proteins.
This approach revealed that helicase-like transcrip-
tion factor (HLTF), a DNA helicase important in DNA
repair, potently inhibits early viral gene expression
but is rapidly degraded during infection. The func-
tionally unknown HCMV protein UL145 facilitates
HLTF degradation by recruiting the Cullin4 E3 ligase
complex. Our approach and data will enable further
identifications of innate pathways targeted by
HCMV and other viruses.
INTRODUCTION
Human cytomegalovirus (HCMV) is a ubiquitous herpesvirus that
persistently infects the majority of the world’s population
(Mocarski et al., 2013). Following primary infection, HCMV es-
tablishes a lifelong latent infection under the control of a healthy
immune system (Reeves et al., 2005). Reactivation from viral
latency to productive infection causes serious disease in immu-Cell Host & Microbe 24, 447–460, Septe
This is an open access article undnocompromised individuals, particularly transplant recipients
and AIDS patients (Nichols et al., 2002). Primary infection and
reactivation in utero are leading causes of deafness and mental
retardation in newborns, affecting approximately 1 in 200 preg-
nancies (Mocarski et al., 2013).
Susceptibility to viral infection and disease is determined in
part by antiviral restriction factors (ARFs) and the viral proteins
that have evolved to degrade them (Duggal and Emerman,
2012). Small-molecule disruption of the interaction between an
ARF and a viral antagonist can enable endogenous inhibition of
viral replication (Nathans et al., 2008). The identification and
characterization of ARFs therefore has important implications
for antiviral therapy, and is particularly important for HCMV, for
which only a few drugs are available.
HCMV is a paradigm for viral immune evasion, encoding at
least 14 proteins that inhibit natural killer (NK) or T cell activation.
A common final pathway for many host protein targets is protea-
somal or lysosomal degradation (reviewed in Halenius et al.,
2015). HCMV also modulates intrinsic immunity to facilitate viral
replication, degrading components of cellular promyelocytic
leukemia nuclear bodies (PML-NB) Sp100, MORC3, and DAXX
that act as restriction factors (Kim et al., 2011; Schreiner and
Wodrich, 2013; Sloan et al., 2016; Tavalai et al., 2011). We
previously published a systematic temporal analysis that
detailed how HCMV orchestrates the expression of >8,000
cellular proteins over the whole course of infection (Weekes
et al., 2014). However, >900 proteins were downregulated
>3-fold, making challenging the prediction of which molecules
aremost likely to perform functions in adaptive and innate immu-
nity. Similarly high numbers of protein targets have subsequently
been observed in systematic studies of infections by other
viruses, for example Epstein-Barr virus (Ersing et al., 2017) and
HIV (Matheson et al., 2015).
Here, we describe a multiplexed proteomic approach to
identify molecules of key functional importance in innate immu-
nity, on the basis of their active proteasomal or lysosomalmber 12, 2018 ª 2018 The Authors. Published by Elsevier Inc. 447
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Identification of Proteins Targeted for Proteasomal or Lysosomal Degradation by HCMV Using an Inhibitor-Based Proteomic
Screen
(A) Schematic of the experimental workflow. Three similar experiments were conducted, examining 12, 18, and 24 hr of HCMV infection; the workflow il-
lustrates the 12-hr analysis. The HFFF-TERT cells used for this analysis behaved extremely similarly to primary HFFFs upon infection with HCMV (Fig-
ure S1D). A comparison of two different protocols for ‘‘mock’’ infection suggested that no adventitious factors were carried along in our viral preparations
(Figure S1E).
(B) Examples of positive controls from the existing literature that were validated by this screen. A ‘‘rescue ratio’’ was calculated as shown: (protein abundance
during HCMV infection with inhibitor/abundance during infection without inhibitor) [b]/(protein abundance during mock infection with inhibitor/abundancewithout
inhibitor) [a]. [a] was limited to a minimum of 1 to avoid artificial ratio inflation. As these ratios were approximately normally distributed (Figure S1B), Benjamini-
Hochberg adjusted significance A values were used to estimate p values (see STARMethods). *p < 0.05, **p < 0.005, ***p < 0.0005 are shown above the bars for
HCMV + MG132 or HCMV + leupeptin. Further examples are shown in Figure S2A.
(C) Number of proteins rescued by MG132 or leupeptin at each time point studied. A stringent filter was employed that required >1.5-fold downregulation during
infection with HCMV or irradiated HCMV, and a rescue ratio of >1.5 with an associated p value of <0.01 (all criteria for each experiment are described in Fig-
ure S1C).
(D) Rescue ratios of all 46 proteins identified by the 12-hr MG132 screen, using stringent criteria.
(legend continued on next page)
448 Cell Host & Microbe 24, 447–460, September 12, 2018
degradation during the early phase of HCMV infection. We
employ three orthogonal tandem mass tag (TMT)-based proteo-
mic screens to measure protein degradation. The first measures
protein abundance throughout early infection in the presence or
absence of inhibitors of the proteasome or lysosome. The sec-
ond employs an unbiased global pulse-chase to compare the
rates of protein degradation during HCMV with mock infection.
The third compares transcript and protein abundance over
time to distinguish between degraded and transcriptionally regu-
lated proteins. Our data provide a comprehensive analysis of
protein degradation and synthesis during early viral infection,
revealing how and when HCMV regulates the expression
of >10,000 host proteins and their transcripts to facilitate replica-
tion and immune evasion.
During productive infection in vitro, HCMV gene expression is
conventionally divided into immediate-early, early, and late
phases over a replication cycle lasting 96 hr. Further definition
can be gained by measuring viral protein profiles over time,
which we have used previously to define five temporal classes
of viral protein expression (Weekes et al., 2014). All herpesvi-
ruses have large genomes, potentially encoding hundreds of
open reading frames (ORFs) (Davison et al., 2013; Stern-Ginos-
sar et al., 2012), meaning that identification of which individual
gene targets a given cellular factor can be challenging. To facil-
itate the mapping of viral gene functions we employed a panel of
HCMV mutants, each deleted in contiguous gene blocks
dispensable for virus replication in vitro. A systematic proteomic
screen of these mutants defined the genetic loci responsible for
targeting >250 host proteins.
A key biological insight from our data is the prediction of ARFs.
The RING E3 ligase helicase-like transcription factor (HLTF) was
proteasomally degraded throughout early infection and potently
inhibits viral immediate-early gene expression. HLTF was found
to be targeted by a protein encoded by the UL/b
0 region in the
HCMV genome (UL133-UL150). Among the proteins encoded
by this region, UL145, which previously had no known function,
was necessary and sufficient for HLTF degradation via recruit-
ment of the Cullin 4/DDB1 ligase complex. Our approach and
data predict molecules of importance in innate antiviral immunity
and will enable further identifications of host pathways targeted
by viruses.
RESULTS
Host Proteins Targeted for Degradation Early during
HCMV Infection
To build a detailed global picture of all host proteins that are
degraded during early HCMV infection, we applied the proteaso-
mal inhibitor MG132 or the lysosomal protease inhibitor leupep-
tin at three early time points during infection of immortalized
primary human fetal foreskin fibroblasts (HFFF-TERTs). Virus in-
activated by irradiation (HCMV*) was included in the experiment
to determine whether components of the virion delivered during(E) Examples of degraded proteins identified using MG132 (top panels), leupepti
panels). Further examples are shown in Figure S2B. Color coding for bars and re
(F) Examples of proteins that were degraded throughout the time course studied
Color coding for bars and rescue ratio p values are as described in (B).the process of infection made a contribution. MG132 is known to
affect lysosomal cathepsins in addition to the proteasome
(Wiertz et al., 1996), and leupeptin is a naturally occurring prote-
ase inhibitor that can inhibit some proteasomal proteases in
addition to the lysosome. Our intention in using these broad,
well-characterized inhibitors was to obtain a comprehensive
list of proteins targeted for degradation by HCMV, rather than
deciphering whether a given protein was degraded in the protea-
some or the lysosome. TMT peptide labels and MS3mass spec-
trometry enabled very precise protein quantitation, as well as
multiplexed analysis of up to 11 samples in the same experiment
(Figure 1A) (McAlister et al., 2014).
We quantified 8,118–8,678 proteins (Figure S1A), and deter-
mined an MG132 and leupeptin ‘‘rescue ratio’’ for each protein,
obtained by comparing protein abundance during HCMV
infection ± inhibitor with protein abundance during mock
infection ± inhibitor (Figure 1B). This ratio enabled identification
of proteins that exhibited increased degradation during HCMV
infection, as opposed to those having a baseline high turnover
in mock-infected cells. Using stringent criteria (Figure S1C),
data were filtered to identify proteins that were most strongly
downregulated by HCMV and most significantly rescued by the
inhibitor. Overall, 131 proteins were rescued by application of
MG132 within 24 hr of infection, with 46 proteins rescued at
12 hr post infection, the earliest time point studied (Figure 1C).
Of the 46 proteins, 7 have already been reported to be degraded
by HCMV, including HCMV restriction factors Sp100 and
MORC3 (Kim et al., 2011; Sloan et al., 2016; Tavalai et al.,
2011), E3 ubiquitin ligases ANAPC1, 4, and 5 (anaphase promot-
ing complex subunits 1, 4, and 5) and ITCH (itchy E3 ubiquitin
protein ligase) (Figures 1B and S2A) (reviewed in Weekes et al.,
2014). The remaining 39 proteins have not previously been
reported to be targeted for proteasomal degradation by
HCMV, including HLTF (Figures 1D and 1E).
Overall, 28 proteins were rescued by application of leupeptin,
of which 50%were also rescued by MG132 (Figures 1C, 1E, and
S2B). Of these proteins, 12 were rescued at 12 hr post infection,
including connexin family gap junction protein alpha 1 (GJA1),
which has previously been reported to be degraded during
HCMV infection (Stanton et al., 2007). Among other findings,
we now report early rescue of E3 ligases neural precursor
cell expressed, developmentally downregulated 4 (NEDD4)
and NEDD4-like (NEDD4L). Some proteins were degraded
throughout early infection, whereas others including ephrin re-
ceptor B3 (EPHB3) were most significantly degraded during a
more limited interval, which may reflect the kinetics of expres-
sion of the HCMV proteins that target them (Weekes et al.,
2014) (Figures 1F and S2B).
During infection with irradiated HCMV, application of inhibitors
resulted in rescue of 37 proteins (Figure 1C). These included the
HCMV restriction factor DAXX, which is known to be targeted
for degradation by the viral tegument protein pp71 (Schreiner
and Wodrich, 2013). Additional proteins targeted by virionn and MG132 (middle panels), or irradiated HCMV plus either inhibitor (bottom
scue ratio p values are as described in (B).
(HLTF), or restricted to a more limited period of infection (SUGP2 and EPHB3).
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Figure 2. A pSILAC/TMT-Based Screen to Quantify Rates of Protein Degradation and Synthesis
(A) Schematic of the experimental workflow. Experiment 1 is illustrated; the equivalent Experiment 2 instead included time points 0, 2, 3, 4, 5, and 6 hr after
infection. We calculated a p value for the difference between KdegHCMV and Kdegmock as described in STARMethods (Statistical Analysis). If Kdegmock was >0, a
fold change (FCHCMV) in protein abundance in the HCMV-infected sample at 18 hr (Experiment 1) or 6 hr (Experiment 2) was calculated, compared with time point
0 (see also Figure S1C).
(B) Overlap between the inhibitor and pSILAC screens. Blue bars show the number of proteins rescued by MG132 or leupeptin at each time point (Figure 1C).
A given protein was considered to be quantified by pSILAC if measured in either the 6-hr or 18-hr screen. pSILAC data were considered to be consistent with the
inhibitor data if KdegHCMV/Kdegmock > 1.5 or FCHCMV > 1.5 (sensitive criteria, Figure S1C).
(C) 18-hr pSILAC validation of positive controls and targets identified by the inhibitor screen (Figures 1B and 1E). NEDD4L was not quantified in this experiment.
(D) Examples of 6-hr pSILAC data for proteins degraded very early during HCMV infection.
(legend continued on next page)
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components included the fibroblast growth factor receptor Golgi
glycoprotein 1 (GLG1), which has not previously been reported
to play a role in innate immunity (Figure 1E).
Data from all proteomic experiments in this study are shown in
Table S1. Here, the worksheet ‘‘Plots’’ is interactive, enabling
generation of graphs of protein expression of any of the human
and viral proteins quantified. Table S2 shows lists of proteins
identified by each screen.
Stability of Viral Proteins
To identify as many HCMV proteins as possible, we used a pro-
tein database that included 170 canonical ORFs most likely to
encode functional proteins, 604 non-canonical ORFs identified
as potentially protein-coding by ribosome profiling (Stern-Ginos-
sar et al., 2012), and all ORFs ofR8 amino acids from a six-frame
translation of the HCMV strain Merlin sequence. This analysis
identified expression of 139 of 170 canonical ORFs, 27 of 604
non-canonical ORFs, and 13ORFs from the six-frame translation
(6FT-ORFs) that had not previously been recognized, some of
these from multiple peptides. Of the 13 6FT-ORFs, 11 were en-
coded in alternative reading frames from canonical ORFs, and
2 represented 50-terminal extensions of previously described
ORFs (one of canonical US20 and the other of non-canonical
ORFL147C) (Figure S1A and Data S1).
The application of MG132 during infection led to substantial
changes in the abundance of a number of viral proteins, particu-
larly at 18 hr and 24 hr post infection. The most substantially
rescued proteins included non-canonical ORFs or 6FT-ORFs.
Leupeptin led to less substantial, but nevertheless significant
changes (Figure S2C). One possible explanation may be that a
subset of non-canonical ORFs represents rapidly degraded
translation ‘‘noise,’’ encoding proteins that are likely to be un-
structured and inherently unstable. This hypothesis is consistent
with a comparison of the disposition of the 13 6FT-ORFs in the
genome sequences of 244 HCMV strains, which suggested
that at least 12 are unlikely to encode functional proteins (Data
S1). Another possibility is that certain viral proteins are rapidly
co-degraded with human target proteins. We have previously re-
ported that HCMV UL138 is co-degraded in the lysosome with
the multi-drug transporter ABCC1 (Weekes et al., 2013) and
that the ten US12-US21 proteins target certain cell-surface pro-
teins for lysosomal degradation (Fielding et al., 2017). UL138 and
5 of the 5 quantified US12-US21 proteins were all substantially
rescued by leupeptin (Figure S2C), suggesting that the group
of viral proteins that exhibit the greatest rescue by inhibitors
may be enriched in molecules that regulate important host
targets.
Global Overview of Protein Synthesis and Degradation
during Infection in an Unbiased Pulsed SILAC/TMT
Screen
To address protein stability and turnover using an orthogonal
approach, we combined pulsed SILAC (stable isotope labeling(E) Twenty-eight viral and four human proteins synthesized to significantly greater
6-hr pSILAC analysis (filters and p-value calculations described in STAR Method
(F) Enrichment of pathways within human proteins synthesized at significant leve
Filters were as described in (E).
For (C), (D), and (E), *p < 0.05, **p < 0.005, and ***p < 0.0005.with amino acids in cell culture) (pSILAC) with TMT to compare
the rates of protein degradation during HCMV and mock
infection (degradation rate constants: KdegHCMV, Kdegmock).
Compared with SILAC-only experiments, benefits of this multi-
plexed approach were a dramatic reduction in the amount of
mass spectrometry time required, and the measurement of
each protein at every time point, avoiding problems caused by
proteins being quantified in some but not all samples. Two
screens examined the first 6 hr or first 18 hr of infection (Figures
2A and S3A). Of the proteins degraded at one or more time
points in the inhibitor screen, 49% (MG132) and 38% (leupeptin)
exhibited an increased rate of degradation by pSILAC (Figures
2B, 2C, S2A, and S2B). In some cases, proteins were degraded
extremely early during infection. For example, a significant differ-
ence was observed between HCMV and mock infection within
4 hr for HLTF, DAXX, and GLG1 (Figure 2D). Degradation of the
restriction factor DAXX has been shown to play a vital role in acti-
vation of immediate-early HCMV gene expression (reviewed in
Schreiner and Wodrich, 2013). Similarly prompt degradation of
HLTF andGLG1 suggests that these proteinsmay play an impor-
tant role in the early part of the viral life cycle.
Of 46 proteins rescued at 12 hr with MG132, 36 were quan-
tified in pSILAC and 24 of 36 exhibited increased degradation
in HCMV-infected cells compared with mock infection. We
investigated 12 out of 36 proteins that were rescued at
12 hr with MG132 and yet did not exhibit instability by pSI-
LAC. In 3 of 12 cases, the protein did not start to exhibit
increased degradation during the 6-hr pSILAC screen and
was not quantified in the 18-hr analysis (for example,
NEDD4, Figure S2B). In 2 of 12 cases, KdegHCMV/Kdegmock
or FCCMV was >1 but <1.5 (for example, PHLDB2, Figure S3B).
Thioredoxin-interacting protein (TXNIP) was extremely rapidly
turned over during mock infection, making it difficult to assess
a difference between mock and HCMV infection even during
the 6-hr pulse. Pleckstrin homology-like domain family A
member 1 (PHLDA1) was rescued significantly by the applica-
tion of MG132 during mock infection, and this may have made
the rescue ratio (which is a ratio of ratios) less precise. Overall,
at least 50% of proteins that were rescued by MG132 but did
not exhibit instability by pSILAC may nevertheless be
degraded, and in some cases transcriptional downregulation
and post-translational controls may have worked in combina-
tion (Figure S3B).
pSILAC enabled the rate of synthesis of each protein in
HCMV-infected (KsynHCMV) and mock-infected cells (Ksynmock)
to be compared. It was also possible to distinguish heavy-
labeled proteins synthesized after infection from light-labeled
proteins delivered in the viral particle. In the 6 hr pulse-chase,
28 viral and 4 human proteins were synthesized to significantly
greater levels in HCMV-infected cells compared with mock-in-
fected cells; all 4 human proteins are known to be interferon
responsive (Figure 2E) (Rusinova et al., 2013). By 18 hr of
pulse-chase, 72 viral and 64 human proteins were synthesizedlevels in HCMV-infected cells compared with mock-infected cells from the 0- to
s [Statistical Analysis]). Example plots are shown in the lower part of the figure.
ls during the 0- to 18-hr analysis, using DAVID software (see also Table S3C).
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Figure 3. Comparative Analysis of Transcript and Protein Abundance to Identify the Mechanism of Host Protein Regulation
(A) Schematic of the experimental workflow.
(B) K-means-based hierarchical cluster analysis of 7,516 proteins and transcripts, identifying global mechanisms of protein regulation by HCMV. Right panels
show examples of each class.
(C) Examples of data for proteins shown in Figures 1B, 1E, and 2C. DAXX was not well quantified in RNA-seq.at significantly greater levels (Tables S3A and S3B). Application
of DAVID software (Huang da et al., 2009) to determine which
pathways were enriched among these proteins indicated the
upregulation of multiple pro-apoptotic transcription factors,
complement components important in innate immunity, and
known ARFs including MX1, MX2, DDX58, and ZC3HAV1.
These proteins are likely to represent the components of an
early cellular response to viral infection (Figure 2F and
Table S3C).
Transcriptional and Post-transcriptional Regulation of
Expression
To identify where protein expression was determined primarily
by mRNA levels rather than being regulated at a post-transcrip-
tional level, we compared transcript and protein abundance
over time. When downregulation of a given protein was accom-
panied by transcript upregulation, it is likely that the protein
was degraded. Thus, integration of an RNA/protein dataset
with the other screens would identify the proteins that were452 Cell Host & Microbe 24, 447–460, September 12, 2018degraded during infection, in addition to providing a global
analysis of how viral infection regulates the host proteome
and transcriptome. We published previously a temporal anal-
ysis of >8,000 proteins over eight time points spanning the
course of infection (Weekes et al., 2014). We now compared
data for human proteins with RNA sequencing (RNA-seq) anal-
ysis from samples derived from simultaneous infections and
harvests (Figure 3A).
The k-means method is useful for clustering proteins into a
specified number of classes based on the similarity of kinetic
expression profiles. K-means clustering with 1–20 classes sug-
gested there were at least seven different patterns of expression
of RNA and protein (Figures 3B and S4A; Table S2). Clusters 1
and 2 chiefly comprised proteins that were transcriptionally
upregulated, including CD55, which is known to be upregulated
during infection. Cluster 5 included proteins that were initially
upregulated at the level of transcription and then downregulated.
Cluster 6 included transcriptionally downregulated proteins,
including CD13/alanyl aminopeptidase (ANPEP). Cluster 7 was
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Figure 4. Complementarity between Individual Screens Identified a Shortlist of Proteins Enriched in Ubiquitin E3 Ligases, Including HLTF
(A) DAVID analysis of pathway enrichment among proteins identified by each screen (stringent criteria, Figure S1C). Benjamini-Hochberg adjusted p values are
shown for each pathway. See also STAR Methods (Pathway Analysis).
(B) Enrichment of pathways using DAVID software as described in (A).
(C) Immunoblot confirmed rescue of HLTF by MG132 (MOI = 5, 12-hr infection, MG132 applied from 0 to 12 hr).enriched in proteins known to be degraded during HCMV infec-
tion, including the NK-activating ligand CD112/nectin cell adhe-
sion molecule 2 (NECTIN2) (reviewed in Weekes et al., 2014), as
well as multiple ‘‘hits’’ from the inhibitor and pSILAC screens
(Table S2).
Multiple proteins identified as degraded by other screens
were also identified by the RNA/protein screen, including
most of those shown in Figures 1B, 1E, S2A, and S2B. How-
ever, certain proteins were not identified, usually as a result
of the stringent criteria applied (Figure S1C). For example,
protein tyrosine phosphatase, non-receptor type 14 (PTPN14)
protein was downregulated >12-fold during infection, but the
transcript was downregulated 1.1- to 1.4-fold as opposed to
being upregulated, which was a requirement of the screen (Fig-
ure 3C). Nevertheless, from these kinetics and the results of the
other two screens it is likely that PTPN14 is degraded, suggest-
ing that an overall shortlist of ‘‘high-confidence’’ degraded
proteins should include those passing at least 2 out of 3
screening tests.
Degradation of Multiple E3 Ubiquitin Ligases Early
during HCMV Infection
We applied DAVID software (Huang da et al., 2009) to determine
which pathways were enriched among degraded proteins from
each individual screen. The results suggested that multiple
plasma membrane proteins may be degraded during infection,
in particular proteins that include a pleckstrin homology (PLEKH)
domain (for example PLEKHA5) or that function in cell-to-cell
adhesion (Figures 4A and S5A; Tables S4A–S4C). We found pre-
viously that HCMV rapidly downregulates multiple g-protocad-
herins (PCDHGC). We now show that a subset of these proteins
are degraded early during infection, including PCDHGB5, sup-
porting the suggestion that these might be NK or T cell ligands
or cellular receptors for HCMV (Figure S5A and Table S4B)
(Weekes et al., 2014). We report that ANAPC2, in addition to
ANAPC1, 4, and 5, is degraded early during HCMV infection,
suggesting that inhibition of these proteins may be of particularimportance in subverting the host cell-cycle machinery during
infection.
To identify with highest confidence the proteins that are
degraded during infection, we combined data from all three
screens. A ‘‘medium-confidence’’ shortlist included a total of
133 proteins degraded in R1 out of 3 screens by stringent
criteria and degraded in at least one other screen by sensitive
criteria (Figure S1C and Table S2). A ‘‘high-confidence’’ shortlist
included 35 proteins that were degraded in at least 2 out of
3 screens by stringent criteria, with 7 proteins degraded in all
3 screens (Figure 4B and Table S2). As expected, the majority
of proteins in both shortlists appeared in cluster 7 from the
RNA/protein analysis (Figures 3B and S5B).
‘‘Ubiquitin-mediated proteolysis’’ was the only significantly en-
riched pathway within the ‘‘high-confidence’’ shortlist, and
included 6 ubiquitin E3 ligases (Figure 4B, Tables S2 and S4E).
A comprehensive search of all 35 ‘‘high-confidence’’ proteins
for E3 ligase activity identified one additional ligase, HLTF.
HLTF was degraded in all three screens, and throughout early
infection starting from 4 hr (Figures 1F, 2D, and 3C), which was
confirmed by immunoblot (Figure 4C). This suggested that
HLTF might play a key functional role in early viral infection,
possibly beingdegradedby the virus to evadeantiviral restriction.
HLTF is known to participate in error-free post-replication
DNA-damage tolerance by binding to nascent single-stranded
DNA and ubiquitinating DNA replication processivity factor
(PCNA) at the stalled replication fork. HLTF thereby facilitates
fork regression and reconvenes DNA replication (Achar et al.,
2011; Blastyak et al., 2010). Functional domains in HLTF include
an RING E3 ligase domain close to the C terminus, an N-terminal
DNA-binding HIRAN (HIP116 Rad5p N-terminal) domain, and
ATPase/helicase domains (Achar et al., 2011). Two recent
studies have suggested that HIV Vpr also degrades HLTF in
a proteasome-dependent manner, by redirecting the Cullin
4/DCAF1 E3 ligase complex, although neither study demon-
strated why this is of functional importance to HIV (Hrecka
et al., 2016; Lahouassa et al., 2016).Cell Host & Microbe 24, 447–460, September 12, 2018 453
HCMV UL145 Is Necessary and Sufficient to
Degrade HLTF
HCMV is the largest human herpesvirus, potentially encoding
hundreds of proteins (Mocarski et al., 2013; Stern-Ginossar
et al., 2012). Given the large and uncertain numbers of functional
proteins, identification of which viral protein targets a given
cellular factor can be a challenging task. We took a systematic
approach to identify the proteins targeting HLTF, initially by
employing a panel of recombinant viruses deleted for one or
other of a series of blocks of genes non-essential for replication
in vitro (Fielding et al., 2014) (Table S5A). Ten block deletion
viruses were screened in two parallel multiplexed proteomic
analyses, with most blocks analyzed in biological duplicate.
For each human protein target, a Z score and fold change (FC)
compared with wild-type (wt) infection were calculated as
described in STAR Methods. To confidently assign modulated
cellular proteins to viral blocks, stringent criteria with a final
Z score of >6 and FC >2 assigned 91 proteins, and sensitive
criteria with a final Z score of >5 and FC >1.5 assigned 251
proteins (Figures 5A, 5B, and S6A, all predictions shown in
Table S6).
The data were validated from multiple positive controls,
including the 14 known targets of the US1-US11 block, such
as HLA-A, -B, and -C molecules, a integrins ITGA2, 4, and 6,
and butyrophilin 2A1 (BTN2A1) (Hsu et al., 2015). Nineteen
known targets of the US18-US22 block were additionally
confirmed, as well as our previous report that ABCC1 is targeted
by UL138, a UL/b
0 gene (Figures 5A, 5B, and S6B; Table S6)
(Fielding et al., 2014; Weekes et al., 2013). HLTF was targeted
by a single viral block, UL/b
0, and this was confirmed by immuno-
blot (Figures 5A and 5C).
This analysis also enabled an examination of which blocks of
viral genes are most important in the regulation of host factors.
There was striking block-to-block variation, with three blocks,
US1-US11, US18-US22, and UL/b
0 each regulating >15 (strin-
gent) or >35 (sensitive) proteins (Figure 5B). By sensitive criteria,
the US12-US17 block was similarly important, regulating 59 pro-
teins (Figure S6A). It is possible that protein Z scores from this
block were lower due to frequent co-regulation of protein targets
with the US18-US22 block (Fielding et al., 2017). Other blocks
had few or no protein targets, suggesting that the proteins they
encode may not be dominantly directed toward regulation of
the host proteome.
To determine which individual proteins target HLTF for degra-
dation, we generated a library of HCMVmutants with deletions of
single canonical genes in UL/b
0 (Table S5B). Only deletion of
UL145 rescued expression of HLTF (Figure 5D). Overexpression
of a C-terminally V5-tagged UL145 (UL145-V5) was sufficient to
downregulate HLTF, and the expression of both proteins was
rescued by MG132, which may suggest co-degradation in the
proteasome (Figure 5E). UL145 was one of the viral proteins
most substantially rescued byMG132, at each time point studied
in the inhibitor screen (Figures S2C and S6C). Both UL145
transcript and newly synthesized protein were detected from
6 hr of infection (Figures 5F and 5G), confirming that the protein
is expressed sufficiently early to regulate HLTF.
The gene encoding UL145 is located between UL144 and
UL146, which exhibit high sequence variability (Dolan et al.,
2004). In contrast, UL145 is well conserved (Sun et al., 2007),454 Cell Host & Microbe 24, 447–460, September 12, 2018with our assessment of UL145 sequences from 242 genome
sequences indicating identity levels of 80% and 83% at the
nucleotide and amino acid sequence levels, respectively (data
not shown). The presence of UL145 orthologs in Old and New
World primate cytomegaloviruses indicates that this gene has
existed for many millions of years (Figure S6D). Thus, although
UL145 is not essential for viral replication in vitro, it is likely to
play an important role in promoting HCMV persistence.
HCMV UL145 Recruits the Cullin4 E3 Ligase Complex to
Target HLTF to the Proteasome
To identify cellular factors interacting with UL145, we performed
a SILAC immunoprecipitation in HFFF-TERTs stably expressing
UL145-V5 (Figure 6A). Cullin 4A (CUL4A) and adaptor molecules
damage-specific DNA-binding protein 1 (DDB1) and DET1- and
DDB1-associated protein 1 (DDA1) all co-precipitated with
UL145 (Figure 6B). Small interfering RNA (siRNA) knockdown
of CUL4A inhibited UL145-mediated HLTF downregulation, sug-
gesting that UL145 may redirect the Cullin4 ligase complex to
degrade HLTF, in a similar manner to HIV Vpr (Figure 6C). Vpr
and UL145 are both small, soluble 14-kDa proteins. Vpr is known
to form three a helices folded around a hydrophobic core; this
structure is important for interactions with HLTF and other
targets, including uracil DNA glycosylase (UNG) (Wu et al.,
2016). UL145 is also predicted to form three a helices (Fig-
ure S6D), hinting that both proteins may have evolved a similar
structure to degrade HLTF.
HLTF is known to localize predominantly to the nucleus,
consistent with its function in DNA repair (Sheridan et al.,
1995). To determine the subcellular localization of UL145, we
generated a recombinant Merlin strain HCMV with a C-terminal
UL145 V5-tag. As expected, infected cells exhibited very low-
level expression of HLTF (Figure 6D). Both proteins exhibited a
predominantly nuclear localization, although some HLTF formed
perinuclear cytoplasmic speckles. Cullin4A localizes to the
nucleus via a nuclear localization signal (Jackson and Xiong,
2009). The Cullin4A-mediated degradation of HLTF may there-
fore occur via the nuclear ubiquitin-proteasome system.
To determine whether UL145 has other cellular targets in addi-
tion to HLTF, we performed an unbiased proteomic comparison
of HFFF-TERTs infected with WT or DUL145 virus. The double-
strand break repair protein tumor protein p53-binding protein 1
(TP53BP1) was rescued both by DUL145 and DUL/b
0 viruses,
compared with WT infection (Figures 6E and S6E), suggesting
that UL145may havewider roles inmodulating theDNA-damage
response.
HLTF Restricts HCMV Early in Infection
We sought to determine whether HLTF acts as a restriction fac-
tor. To identify HCMV-infected cells, we cloned enhanced GFP
(EGFP) as a C-terminal fusion with the immediate-early gene
UL36, with a self-cleaving P2A peptide releasing the reporter
following synthesis. UL36 was chosen for this analysis since
we found it to be among the most abundantly expressed viral
proteins within the first 6 hr of infection, and the insertion of
GFP did not impede UL36 function (Figures 7A and 7B). We
adapted an assay previously deployed to examine the role of
PML-NB components in HCMV restriction (Tavalai et al., 2011)
(Figure 7C). The PML-NB protein Sp100 acts to restrict HCMV
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Figure 5. A Proteomic Screen of Viral Block Deletion Mutants Revealed that the UL/b
0 gene UL145 Targets HLTF
(A) Regulation of >250 cellular proteins (MOI = 10, 72-hr infection). Due to the multiplexing limits of TMT analysis, two separate screens were needed to
encompass all viruses. HCMV strain AD169 was used for the UL/b
0 mutant, as a deletion in this region (plus additional defects) has been acquired during passage
in culture. Strain AD169, strain Merlin DUS27-US28, DUL13-UL20, and DUS12-US17 mutants were only examined in single screens, with all other viruses
examined in duplicate. Example results are shown for HLA-A11 and HLTF. For HLTF, peptides were quantified in only one of the two screens. Further details are
given in STAR Methods (Statistical Analysis).
(B) Numbers of human proteins targeted by each block using stringent scoring (Z score of >6 and FC > 2, left panel). For each block, the Z scores of all proteins
that passed the stringent scoring criteria are shown (right panel).
(C) Immunoblot confirming that HLTF is downregulated by strain Merlin but not strain AD169 (MOI = 5, 24-hr infection).
(D) Immunoblot showing UL145 is necessary for downregulation of HLTF (HCMV UL/b
0 single gene-deletion viruses used at MOI = 5, 72-hr infection).
(E) Immunoblot of stably transduced HFFF-TERTs showing UL145 is sufficient for downregulation of HLTF.
(F) UL145 protein is expressed from at least 6 hr post infection (earliest time point studied in pSILAC 0- to 18-hr data, Figure 2). UL145 RNAwas detected by RNA-
seq from 24 hr post infection, the earliest time point studied in the RNA/protein screen (Figure 3).
(G) Detection of UL145 transcript from 6 hr of infection at MOI = 1 by qRT-PCR. Error bars show SEM for technical quadruplicates.infection and was thus selected as a positive control. Sp100
depletion consistently enhanced HCMV UL36-GFP expression
in four independent experiments (Figure 7D). This effect was
highly dependent on the viral dose. The enhancement of virusinfection with Sp100 knockdown was much more pronounced
at lower MOIs as has been previously reported, possibly
explained by efficient viral antagonism of Sp100 at higher MOI
(Tavalai et al., 2011). Remarkably similar results were observedCell Host & Microbe 24, 447–460, September 12, 2018 455
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Figure 6. HCMV UL145 Degrades HLTF via the Cullin 4E3 Ligase Complex, and Additionally Targets TP53BP1
(A) Schematic of SILAC immunoprecipitation (IP). MS, mass spectrometry.
(B) Results of SILAC immunoprecipitation. The fold enrichment of each protein is shown. p values were estimated using significance A values, then corrected for
multiple hypothesis testing (Cox and Mann, 2008). Proteins enriched with p < 0.05 are shown in the graph.
(C) Immunoblot showing HCMV UL145 downregulates HLTF in a CUL4A-dependent manner. 293T cells stably expressing UL145-V5 or vector control were
treated with control siRNA, or siRNA against CUL4A for 48 hr.
(D) Immunofluorescence demonstrated nuclear localization of UL145 (MOI = 0.1, 24-hr infection with Merlin strain recombinant with a C-terminal UL145 V5 tag).
(E) UL145 targets TP53BP1 in addition to HLTF. HFFF-TERTs were infected with WTor DUL145 HCMV at MOI = 5 for 72 hr. Shown are proteins quantified byR2
peptides and rescued >1.5-fold both by DUL145 compared with wt, and by the UL/b
0 block deletion compared with WT (Figure 5A). Values displayed are the
minimum fold change and the maximum p value from the DUL145/wt and UL/b
0/wt experiments. Benjamini-Hochberg-corrected significance A was used to
estimate p values.with short hairpin RNA (shRNA) knockdown of HLTF. At lowMOI,
knockdown of HLTF significantly increased the efficiency of virus
infection in two independent HFFF-TERT lines stably transduced
with different HLTF shRNA constructs (Figures 7D and 7E). The
enhancement of HCMV infection was confirmed using five inde-
pendently derived CRISPR/Cas9 knockdown lines for both
Sp100 and HLTF (Figure 7F). HLTF thus acts to restrict signifi-
cantly the efficiency with which a low MOI HCMV infection acti-
vates immediate-early gene expression, with an efficiency
similar to that of the recognized HCMV restriction factor Sp100.
DISCUSSION
Herpesviruses achieve lifelong persistence in infected individ-
uals by utilizing a wide range of strategies to modulate innate
and adaptive immunity. These include the deployment of
proteins to target host factors for degradation. For example,456 Cell Host & Microbe 24, 447–460, September 12, 2018the HCMV US2 protein targets at least ten cell-surface mole-
cules to the proteasome, including the NK-activating ligand
CD112 and major histocompatibility complex class I (Hsu
et al., 2015). The ten members of the US12 gene family act in
concert to suppress the expression of cell-surface immune
ligands, with many targeted for lysosomal degradation (Fielding
et al., 2017). The degradation of intrinsic cellular restriction
factors (e.g., Sp100, DAXX, and MORC3) is induced by virion
components or viral proteins expressed early in infection and
dramatically enhances the efficiency of infection (Schreiner and
Wodrich, 2013; Sloan et al., 2016; Tavalai et al., 2011).
We now provide a searchable database that systematically
details the synthesis and degradation of >10,000 cellular and
viral proteins during the establishment of a productive HCMV
infection. Our data provide a significant insight into how this virus
regulates the stability of each protein including the route and rate
of degradation, and predict molecules of key importance in
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Figure 7. HLTF Restricts Early HCMV Infection
(A) Viral proteins with the highest cellular concentration, estimated using a ‘‘proteomic ruler’’ approach (Wisniewski et al., 2014) with data from the 0- to 6-hr
pSILAC experiment. A UL123 C-terminal GFP tag impaired viral growth. A similar problem occurred with UL135 (data not shown). The inhibitor of apoptosis UL36,
which was the fourth most abundant viral protein, was therefore selected and C-terminally tagged with a self-cleaving P2A peptide followed by EGFP.
(B) A C-terminal UL36-GFP tag does not impair protein UL36 function. Cells were infected with the indicated virus for 24 hr, then treatedwith cycloheximide (CHX)
and a crosslinking Fas antibody. A viability dye was used to quantify live cells by flow cytometry. Data were normalized to the number of live cells in the absence of
Fas antibody. UL36-P2A-GFP virus was comparable withwt, whereas virus lacking UL36was significantlymore sensitive to Fas-mediated apoptosis. *p < 0.05 by
two-way ANOVA (n = 3).
(C) Schematic of the restriction assay. HFFF-TERTs were infected at low MOI after stable knockdown for a putative restriction factor or control.
(D) Validation of the restriction assay using shRNA. Representative results from one of four experiments are shown (left panel). At MOI = 0.1, a difference between
shSp100 and shControl cells was no longer detectable, suggesting that the antiviral activity of Sp100 was efficiently overcome. In the same experiment, HLTF
restricted infection similarly to Sp100. Values shown are mean ± SEM p values for a difference between shSp100 or shHLTF, and control cells were estimated
using a two-tailed t test (n = 3). *p < 0.05 (for both Sp100 and HLTF where indicated). Immunoblot confirmed knockdown of all Sp100 isoforms (right panel) and
HLTF (E).
(E) HLTF restricts early HCMV infection. Application of the restriction assay at low MOI using two different shHLTF vectors suggested that HLTF restricted
infection at least as potently as Sp100 (left panel). p values were estimated using a two-tailed t test (n = 3). **p < 0.005, ***p < 0.0005.
(F) Confirmation that HLTF restricts early HCMV infection using five independent polyclonal CRISPR/Cas9 Sp100 and HLTF cell lines. Each employed integrated
guide RNAs (gRNAs) with different target sequences within a given gene. Control cells expressing non-targeting gRNAs were generated in a similar manner (right
panels; superfluous lanes from the HLTF and corresponding GAPDH gel have been digitally eliminated as indicated by the dashed line). Infection at MOI = 0.01
identified a substantial increase in viral replication in knockdown compared with control cells (left panels). p values were estimated using a two-tailed t test (n = 3).
*p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005.
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innate antiviral immunity to HCMV. Furthermore, data from a
comprehensive panel of viral mutants enable identification of
the viral genes that target >250 host proteins, and have distin-
guished four key genetic ‘‘hubs’’ of regulation, including UL13-
UL20, UL133-UL150 (UL/b
0), US1-US11, and US27-US28.
Further information could now be gained by studying individual
gene-deletion mutants for each of these hubs.
HCMV orchestrates the regulation of host gene expression
through a relatively long replication cycle (>72 hr) to facilitate viral
replication while evading immune defenses. The calculated me-
dian protein half-life of 58.4 hr in uninfected fibroblasts suggests
that degradation may be the only mechanism that can achieve
sufficiently rapid change in a subset of proteins downregulated
early during infection. For example, 18% of proteins downre-
gulated >3-fold within 24 hr of infection were regulated primarily
by mRNA levels, but 32%–54% were targeted for degradation
(using high- or medium-confidence criteria, respectively). Of
these degraded proteins, 87%–89% were targeted to the
proteasome (as assessed by MG132), suggesting that the lyso-
somal route is used less commonly. Interestingly, 1%–5% of
proteins were degraded and also had reduced mRNA levels,
suggesting that multiple regulatory mechanisms may be em-
ployed by HCMV for effective control of certain targets. For
example, GJA1 has been reported to be degraded in the protea-
some (Stanton et al., 2007). The MG132 and pSILAC screens
confirmed this finding, although the RNA-seq and leupeptin
data suggested that GJA1 is also transcriptionally downregu-
lated and targeted to the lysosome.
In addition to degradation, mechanisms such as intracellular
sequestration play a role in downregulation of proteins from
organelles such as the plasma membrane (PM). For example,
we and others have reported that the NK-activating ligands
poliovirus receptor, MICB, and ULBP1-2 are downregulated
from the cell surface while accumulating in the ER, retained by
HCMV UL141 or UL16. By 24 hr of infection, such sequestered
proteins were downregulated >2-fold from the PM but were
not downregulated in whole-cell lysates (Weekes et al., 2014).
Overall, this trend was observed for only 1.6% of PM proteins,
suggesting that the predominant mechanism HCMV employs
to downregulate proteins during the early phase of infection is
proteasomal degradation.
Additional insights gained from these data include the quanti-
tation of the majority (139/170) of the current set of canonical
HCMV proteins. This suggests that our approach has sufficient
sensitivity to reveal non-canonical gene usage. A large number
(604) of additional HCMVORFs have been identified by ribosome
profiling as potentially being translated (Stern-Ginossar et al.,
2012), but it is unclear how many represent functional polypep-
tides. We quantified 27 of these ORFs, but only four exhibited
stable expression, which was defined as requiring identification
by >10 peptides across all experiments and not being rescued
byMG132 or leupeptin. For example, one of this set (ORFL147C)
was identified by a total of 129 peptides and was
rescued <1.2-fold by the inhibitors. Of the 13 ORFs identified
from the six-frame translation, all but one lacked substantial con-
servation among HCMV strains or between HCMV and related
viruses, and, where measured, were turned over rapidly in the
proteasome. The exceptional ORF is a 50-terminal extension of
ORFL147C. Overall, the data are supportive of the current defini-458 Cell Host & Microbe 24, 447–460, September 12, 2018tion of the canonical gene set (Davison et al., 2013), but there is a
case for functional investigations of a modest number of addi-
tional ORFs, including ORFL147C.
An example of the power of our techniques and data is the
identification of an innate immune function in HCMV (UL145)
and its cellular target (HTLF). HLTF was initially identified as a
DNA-binding protein, which specifically recognized the SV40
enhancer and HIV-1 promoter (Sheridan et al., 1995). HLTF
also binds directly to the promoters of the human b-globin and
plasminogen activator inhibitor-1 genes to enhance expression,
and associates with transcription factors Sp1 and Sp3, which
can in some cases repress promoters (Ding et al., 1999; Li
et al., 2004). Although the mechanism through which HLTF is
able to restrict HCMV is yet to be elucidated, based on its cellular
functions it may either repress HCMV gene transcription via Sp1/
Sp3 or other factors, or function as an intrinsic viral DNA sensor
that triggers antiviral immunity.
Only three drugs are currently available to treat HCMV infec-
tion, and all suffer from significant side effects and the threat of
the development of resistance. In the context of the increasing
frequency of transplantation, innovative strategies are clearly
required. The identification of a potentially inhibitable interaction
between a cellular restriction factor and a viral antagonist may
therefore be of major therapeutic significance. Ideally, similar
interactions involving several distinct antiviral pathways might
be targeted simultaneously to inhibit viral replication in a way
that is refractory to resistance. This illustrates the crucial poten-
tial of our data to identify additional proteins that have roles in
restricting infection by HCMV or other viruses.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cells and Cell Culture
Primary human fetal foreskin fibroblast cells (HFFFs, male) and HFFFs immortalised with human telomerase (HFFF-TERTs) were
grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with foetal bovine serum (FBC: 10% v/v), and penicillin/strep-
tomycin at 37C in 5% CO2. HFFFs and HFFF-TERTs have been tested at regular intervals since isolation to confirm both that the
HLA & MICA genotypes and the morphology and antibiotic resistances are consistent with the original cells. In addition, the
HCMV Merlin strain used is only permissive in human fibroblasts (dermal or foreskin), further limiting the chances that the cells
have been contaminated with another cell type.
For pulsed SILAC analysis, cells were grown for seven divisions in DMEM for SILAC, which was supplied without light arginine or
lysine. This medium was supplemented with 10% dialysed FBS, penicillin/streptomycin, 84 mg/ml light arginine, 280 mg/l L-proline
and either 50mg/ml medium lysine (Lys 4) or 146mg/ml heavy lysine (Lys 8). For SILAC immunoprecipitations, cells were grown iden-
tically but the medium was supplemented with 10% dialysed FBS, penicillin/streptomycin, 280 mg/l L-proline and either light (Arg 0,
Lys 0) or medium (Arg 6, Lys 4) amino acids at 50mg/l. Incorporation of heavy label was >98% for both arginine and lysine-containing
peptides.
Viruses
We used virus (RCMV1111) derived by transfection of a BAC clone of HCMV strain Merlin, the genome of which is designated the
reference HCMV sequence by the National Center for Biotechnology Information and was sequenced after 3 passages in vitro (Dolan
et al., 2004) (Stanton et al., 2010). RCMV1111 contains point mutations in two genes (RL13 and UL128) that enhance replication in
fibroblasts (Stanton et al., 2010). The 10 block HCMV deletion mutants were generated on a strain Merlin background (wt1), or wt1
that lacked UL16 andUL18 (wt2) by transfection of recombinant BACs (Stanton et al., 2010) as described in (Fielding et al., 2014). The
wt2 background was originally employed to facilitate detection of NK evasion functions (deletion and backbone details shown in
Table S5A) (Fielding et al., 2014). HCMV strain AD169 varUK/BK000394 was used for the UL/b’ mutant, as a deletion in this region
(plus additional defects) has been acquired during passage in culture. Single gene deletion mutants of all the canonical genes in the
UL/b’ region were generated by recombineering the strain Merlin BAC as described previously (Stanton et al., 2010). Whole-genome
consensus sequences of passage 1 of each RCMV were derived using the Illumina platform as described previously (Fielding et al.,
2014), and deposited in GenBank. HCMV expressing rGFP from a P2A self-cleaving peptide following the UL36 ORF, and UL145-V5
recombinants were generated as described in (Fielding et al., 2014). For part of the inhibitor screen, viruses were irradiated with a
dose of 3500 Gy using a Gammacell 1000 Elite (Nordion International), and inactivation was verified by the absence of immunoflu-
orescence for IE1 compared to control (data not shown) (Weekes et al., 2014).
Virus stocks were prepared from HFFF-TERTs as described previously (Stanton et al., 2007). Tissue culture supernatants were
kept when a 100% cytopathic effect was observed, and were centrifuged to remove cell debris. Cell-free virus was pelleted from
supernatant by centrifugation at 22,000 3 g for 2 h and then resuspended in fresh DMEM. Residual debris was removed from the
resulting virus stocks by centrifugation at 16,000 x g for 1 min.e4 Cell Host & Microbe 24, 447–460.e1–e11, September 12, 2018
METHOD DETAILS
Virus Infections and Inhibitors for Proteomic Experiments
1 x 106 HFFFs (RNA/protein screen, block deletion mutant screen) or HFFF-TERTs (inhibitor, pSILAC, wt vs DUL145 virus screens)
were plated in a 25cm2 flask. We found that primary HFFFs were limited to a total of25 passages and exhibited diminished rates of
growth as passage number increased. HFFF-TERTs were therefore used in the pSILAC screen, due the need for seven cell divisions
prior to infection, and in the inhibitor screen to ensure comparability of results. Cells were infected at multiplicity of infection 5 or
10 with HCMV strain Merlin as previously described (Weekes et al., 2014). Briefly, the requisite volume of viral stock was added
to 1 ml DMEM and mixed gently prior to being applied to cells. Mock infections were performed identically but with additional
DMEM instead of viral stock. Time 0 in any experiment was considered to be the initial point of infection with virus. In each
experiment, cells were incubated with virus for 2 h prior to a change in medium with the exception of the 6 h pSILAC experiment,
where cells were incubated with virus for 1.5 h. Inhibitors added at the indicated times were: 10 mM MG132 (Merck) or 200 mM
Leupeptin (Merck).
Pulsed SILAC Analysis
For pulsed SILAC, cells were grown for seven divisions in medium-labelled SILAC DMEM as detailed above. Seeding at 1 x 106 per
T25 gave a confluent culture, resulting in the arrest of cell division by contact inhibition. This ensured that protein turnover was the
sole determinant of labeling kinetics, as opposed to dilution of cellular proteins by cell division. At time 0, media was changed to
heavy-labelled SILACDMEMcontaining HCMVor equivalent virus-freemedium for mock infection. Without frequent media changes,
substantial recycling of medium-labelled amino acids occurred (data not shown). We therefore (a) increased the concentration of
heavy lysine to that of standard DMEM, namely 146 mg/l. (b) changed media every 45 mins for the whole course of the experiment
(18 h pSILAC experiment) or every 30 mins for the whole experiment (6 h pSILAC experiment). Cells were harvested at time points
detailed in Figure 2A. For the 3 h time point in Experiment 2, HCMV-infected and not mock-infected cells were harvested, as only
11 TMT labelling reagents were available.
Whole Cell Lysate Protein Digestion
Cells were washed twice with PBS, and 250 ml lysis buffer added (6M Guanidine/50 mM HEPES pH 8.5). Cell lifters (Corning) were
used to scrape cells in lysis buffer, which was removed to an eppendorf tube, vortexed extensively then sonicated. Cell debris was
removed by centrifuging at 21,000 g for 10 min twice. Although this method prohibited cell counting immediately prior to lysis, it
avoided the need for cellular detachment. Half of each sample was kept for subsequent analysis by immunoblot where required.
For the other half, dithiothreitol (DTT) was added to a final concentration of 5 mM and samples were incubated for 20mins. Cysteines
were alkylated with 14 mM iodoacetamide and incubated 20 min at room temperature in the dark. Excess iodoacetamide was
quenched with DTT for 15 mins. Samples were diluted with 200 mM HEPES pH 8.5 to 1.5 M Guanidine followed by digestion at
room temperature for 3 h with LysC protease at a 1:100 protease-to-protein ratio. Samples were further diluted with 200 mMHEPES
pH 8.5 to 0.5MGuanidine. Trypsin was then added at a 1:100 protease-to-protein ratio followed by overnight incubation at 37C. The
reaction was quenched with 5% formic acid, then centrifuged at 21,000 g for 10 min to remove undigested protein. Peptides were
subjected to C18 solid-phase extraction (SPE, Sep-Pak, Waters) and vacuum-centrifuged to near-dryness.
Peptide Labeling with Tandem Mass Tags
In preparation for TMT labeling, desalted peptideswere dissolved in 200mMHEPESpH 8.5. Peptide concentrationwasmeasured by
microBCA (Pierce), and 25 mg of peptide labeled with TMT reagent. TMT reagents (0.8 mg) were dissolved in 43 ml anhydrous aceto-
nitrile and 3 ml added to peptide at a final acetonitrile concentration of 30% (v/v). Sample labelling was as indicated in Table S7A.
Following incubation at room temperature for 1 h, the reaction was quenched with hydroxylamine to a final concentration of
0.3% (v/v). TMT-labeled samples were combined at a 1:1:1:1:1:1:1:1:1:1:1 ratio. The sample was vacuum-centrifuged to near dry-
ness and subjected to C18 SPE (Sep-Pak, Waters). An unfractionated singleshot was analysed initially to ensure similar peptide
loading across each TMT channel, thus avoiding the need for excessive electronic normalization. As all normalisation factors
were >0.5 and <2, data for each singleshot experiment was analysed with data for the corresponding fractions to increase the overall
number of peptides quantified. Normalisation is discussed in ‘Data Analysis’, and high pH reversed-phase (HpRP) fractionation is
discussed below.
Offline HpRP Fractionation
TMT-labelled tryptic peptides were subjected to HpRP fractionation using an Ultimate 3000 RSLC UHPLC system (Thermo Fisher
Scientific) equipped with a 2.1 mm internal diameter (ID) x 25 cm long, 1.7 mmparticle Kinetix Evo C18 column (Phenomenex). Mobile
phase consisted of A: 3% acetonitrile (MeCN), B: MeCN and C: 200 mM ammonium formate pH 10. Isocratic conditions were
90% A/10% C, and C was maintained at 10% throughout the gradient elution. Separations were conducted at 45C. Samples
were loaded at 200 ml/minute for 5minutes. The flow rate was then increased to 400 ml/minute over 5minutes, after which the gradient
elution proceed as follows: 0-19% B over 10 minutes, 19-34% B over 14.25 minutes, 34-50% B over 8.75 minutes, followed by a
10minutes wash at 90%B. UV absorbance wasmonitored at 280 nm and 15 s fractions were collected into 96 well microplates using
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each column of the plate into a single fraction, and commencing combination of adjacent fractions in alternating rows. Wells were
excluded prior to the start or after the cessation of elution of peptide-rich fractions, as identified from the UV trace. This yielded
two sets of 12 combined fractions, A and B, which were dried in a vacuum centrifuge and resuspended in 10 ml MS solvent (4%
MeCN/5% formic acid) prior to LC-MS3. 12 set ‘A’ fractions were used for MS analysis of all experiments. For the 18 h pSILAC
(pSILAC_18) experiment, an additional 6 set ‘B’ fractions were used, as 6/12 original fractions were suboptimally analysed on the
Orbitrap Lumos. For the 12 h inhibitor experiment (Deg_12), a single fraction failed to run optimally and a further set ‘B’ fraction
was analysed. Both set ‘A’ and set ‘B’ runs were included in the final analysis in each case (Table S7B).
LC-MS3 for TMT and TMT/SILAC Experiments
Mass spectrometry data was acquired using an Orbitrap Lumos for all experiments apart from 6 fractions from the pSILAC_18 exper-
iment, where an Orbitrap Fusion mass spectrometer was used instead (Thermo Fisher Scientific, San Jose, CA). In both cases, an
Ultimate 3000 RSLC nano UHPLC equipped with a 300 mm ID x 5 mm Acclaim PepMap m-Precolumn (Thermo Fisher Scientific)
and a 75 mm ID x 50 cm 2.1 mm particle Acclaim PepMap RSLC analytical column was used.
For Orbitrap Lumos Experiments
Loading solvent was 0.1% FA, analytical solvent A: 0.1% FA and B: 80%MeCN + 0.1% FA. All separations were carried out at 55C.
Samples were loaded at 5 mL/minute for 5 minutes in loading solvent before beginning the analytical gradient. The following gradient
was used: 3-7% B over 3 minutes, 7-37% B over 173 minutes, followed by a 4 minute wash at 95% B and equilibration at 3% B for
15 minutes. Each analysis used a MultiNotch MS3-based TMT method (McAlister et al., 2014). The following settings were used:
MS1: 380-1500 Th, 120,000 Resolution, 2x105 automatic gain control (AGC) target, 50msmaximum injection time. MS2: Quadrupole
isolation at an isolation width of m/z 0.7, CID fragmentation (normalised collision energy (NCE) 35) with ion trap scanning in turbo
mode from m/z 120, 1.5x104 AGC target, 120 ms maximum injection time. MS3: In Synchronous Precursor Selection mode the
top 6 MS2 ions were selected for HCD fragmentation (NCE 65) and scanned in the Orbitrap at 60,000 resolution with an AGC target
of 1x105 and a maximum accumulation time of 150 ms. Ions were not accumulated for all parallelisable time. The entire MS/MS/MS
cycle had a target time of 3 s. Dynamic exclusion was set to +/- 10 ppm for 70 s. MS2 fragmentation was trigged on precursors 5x103
counts and above.
For Orbitrap Fusion Experiments
Loading solvent was 0.1% TFA, analytical solvent A: 0.1% FA and B: MeCN + 0.1% FA. All separations were carried out at 55C.
Samples were loaded at 10 ml/minute for 5 minutes in loading solvent before beginning the analytical gradient. The following gradient
was used: 3-5.6%Bover 4minutes, 5.6-32%Bover 162minutes, followed by a 5minute wash at 80%B and a 5minute wash at 90%
B and equilibration at 3% B for 5 minutes. Each analysis used a MultiNotch MS3-based TMT method (McAlister et al., 2014). The
following settings were used: MS1: 400-1400 Th, Quadrupole isolation, 120,000 Resolution, 2x105 AGC target, 50 ms maximum in-
jection time, ions injected for all parallisable time. MS2: Quadrupole isolation at an isolation width of m/z 0.7, CID fragmentation
(NCE 30) with ion trap scanning out in rapid mode fromm/z 120, 1x104 AGC target, 70 msmaximum injection time, ions accumulated
for all parallisable time in centroid mode. MS3: in Synchronous Precursor Selection mode the top 10MS2 ions were selected for HCD
fragmentation (NCE 65) and scanned in the Orbitrap at 50,000 resolution with an AGC target of 5x104 and a maximum accumulation
time of 150 ms, ions were not accumulated for all parallelisable time. The entire MS/MS/MS cycle had a target time of 3 s. Dynamic
exclusion was set to +/- 10 ppm for 90 s. MS2 fragmentation was trigged on precursors 5x103 counts and above.
Immunoprecipitation and Protein Digestion
Cells were harvested in lysis buffer (50 mM Tris pH 7.5, 300 mM NaCl, 0.5% (v/v) NP40, 1 mM DTT and Roche protease inhibitor
cocktail), tumbled for 15minutes at 4Cand then centrifuged at 16,100 g for 20minutes at 4C. Lysates were then clarified by filtration
through a 0.7 mm filter and incubated for 3 h with immobilised mouse monoclonal anti-V5 agarose resin. Samples were washed
multiple times with lysis buffer, followed by multiple PBS pH 7.4 washes. Subsequently, proteins bound to the anti-V5 resin were
eluted twice by adding 200 ml of 250 mg/ml V5 peptide (Alpha Diagnostic International) in PBS at 37C for 30 minutes with agitation.
Finally, proteins were precipitated with 20% TCA, washed once with 10% TCA, washed three times with cold acetone and dried to
completion using a centrifugal evaporator. Samples were re-suspended in protein loading dye, electrophoresed approximately 2 cm
into a precast SDS-Polyacrylamide gel and stained with SimplyBlue Safe Stain (Novex). The lane was excised, and the proteins
digested in-gel for mass spectrometry on the Orbitrap Lumos.
LC-MS/MS for Immunoprecipitation Experiments
Loading solvent was 3%MeCN, 0.1% FA, analytical solvent A: 0.1% FA and B: MeCN + 0.1% FA. All separations were carried out at
55C. Samples were loaded at 5 ml/minute for 5 minutes in loading solvent before beginning the analytical gradient. The following
gradient was used: 3-40% B over 29 minutes followed by a 3 minute wash at 95% B and equilibration at 3% B for 10 minutes.
The following settings were used: MS1: 300-1500 Th, 120,000 resolution, 4x105 AGC target, 50 ms maximum injection time. MS2:
Quadrupole isolation at an isolation width of m/z 1.6, HCD fragmentation (NCE 35) with fragment ions scanning in the Orbitrap
from m/z 110, 5x104 AGC target, 60 ms maximum injection time, ions accumulated for all parallelisable time. Dynamic exclusion
was set to +/- 10 ppm for 60 s. MS2 fragmentation was trigged on precursors 5x104 counts and above.e6 Cell Host & Microbe 24, 447–460.e1–e11, September 12, 2018
RNAseq Analysis
RNAseq analysis was performed in biological triplicate at three time points of infection: 0h (mock), 24 h and 72 h. For each sample,
RNA was extracted from a 75 cm2 flask of HFFFs infected at moi 10 or mock-infected using an RNeasy Plus kit (Qiagen). Infections
and harvests were performed simultaneously with protein samples for experiment WCL2 (Weekes et al., 2014). Poly(A) RNA was
enriched using a Poly(A)Purist MAG kit (Thermo). 250 ng of poly(A) RNA from each sample was used to prepare a cDNA library using
a PrepX RNA-Seq Library Kit (Wafergen biosystems) on an Apollo 324 (WaferGen biosystems), according to the manufacturer’s
protocol. The following barcode sequences were used: Mock1 (ATCACGAT); Mock2 (CGATGTAT); Mock3 (TTAGGCAT); 24h_1
(TGACCAAT); 24h_2 (ACAGTGAT); 24h_3 (GCCAATAT); 72h_1 (CAGATCAT); 72h_2 (ACTTGAAT); 72h_3 (GATCAGAT). The resulting
libraries were quantified using an Agilent Bioanalyser 2100 (Agilent Technologies, Santa Clara, CA), then were pooled for sequencing
on a single lane of Illumina HiSeq2500 (1 3 50 bp reads).
Plasmid Construction
For exogenous gene expression, a V5-tagged UL145 construct was amplified from an adenoviral template, which expressed UL145-
V5 under the control of a CMVpromoter. Primers were designed to recognise the 3’ end of the CMVpromoter (forward) and the V5 tag
(reverse) (Key Resources Table). A control construct was prepared by annealing two oligonucleotides. Both primers and oligonucle-
otides had flanking Gateway attB sequences (Key Resources Table). PCR employed the PfuUltra II Fusion HS DNA Polymerase
(Agilent). Constructs were subsequently cloned into lentiviral destination vector pHAGE-pSFFV using the Gateway system (Thermo
Scientific). pHAGE-pSFFV has a spleen focus-forming virus (SFFV) promoter replacing the CMV promoter in pHAGE-pCMV to
prevent promoter inactivation during HCMV infection. For shRNA, two partially complementary oligonucleotides (Table S7C) were
annealed. The resulting product was ligated into the pHR-SIREN vector (gift from Prof. Paul Lehner, University of Cambridge) as a
BamHI–EcoRI fragment using T4 ligase (Thermo Scientific). All constructed plasmids were transformed into Alpha-Select Silver
Efficiency Competent E. coli cells (Bioline) at 42C for 1 min and selected on antibiotic-containing LB agar plates.
Stable Cell Line Production
Lentiviral particles were generated through transfection of HEK293T cells with the lentiviral transfer vector plus four helper plasmids
(VSVG, TAT1B, MGPM2, CMV-Rev1B), using TransIT-293 transfection reagent (Mirus) according to the manufacturer’s recommen-
dations. Viral supernatant was typically harvested 48 h after transfection, cell debris was removed with a 0.22 mm filter, and target
cells were transduced for 48 h then subjected to antibiotic selection for two weeks.
CRISPR/Cas9-Mediated Gene Disruption
HFFF-TERT cells stably expressing pHRSIN-PSFFV-Cas9-PPGK-Hygro (gift from Professor Paul Lehner, University of Cambridge)
were transduced with lentivirus employing the pKLV-U6gRNA(BbsI)-PGKpuro2ABFP plasmid (Addgene Plasmid #50946), that
constitutively expressed a given gRNA (Table S7C). Confirmation of protein level reduction in low passage polyclonal populations
of cells expressing both Cas9 and the gRNA of choice was then achieved by immunoblot. Polyclonal selected cell populations
were used in this study.
siRNA Knockdown
24 h prior to transfection, 3x105 293Ts constitutively expressing UL145-V5 or control were plated in 6 well plates. Cells were trans-
fected with a pool of CUL4A siRNAs (L-012610-00, Dharmafect) or a pool of non-targeting siRNAs (D-001810-10, Dharmafect) with
DHARMAfect 1 Transfection Reagent (T-2001, Dharmafect) giving a final siRNA concentration of 25 nM. Cellular lysates were
harvested 48 h post transfection for immunoblot.
Immunoblotting
HFFF-TERTs were used for all experiments apart from Figure 6C, where 293T cells were used. For most immunoblots, cells were
lysed with RIPA buffer (Cell Signaling) containing Complete Protease Inhibitor Cocktail (Roche) and then lysates were sonicated.
For cells infected by single gene deletion viruses, 6 M Guanidine whole cell lysates were precipitated using a ProteoExtract protein
precipitation kit (Calbiochem) and re-dissolved in 2%SDS/Tris 200mM pH 8.5 with sonication. Protein concentration was measured
by BCA (Pierce). Lysates were reducedwith 6X Protein Loading Dye (Tris 375mMpH 6.8, 12%SDS, 30%glycerol, 0.6MDTT, 0.06%
bromophenol blue) for 5 min at 95C. 50 mg of protein for each sample was separated by PAGE using 4-15% TGX Precast Protein
Gels (Bio-rad), then transferred to PVDF membranes using Trans-Blot Systems (Bio-rad). The following primary antibodies were
used: anti-HLTF (ab17984, Abcam), anti-HCMV IE1/2 (ab53495, Abcam), anti-GAPDH (MAB5718, R&D Systems), anti-V5 (MA5-
15253, Thermo), anti-Sp100 (GTX131570, GeneTex). Secondary antibodies were IRDye 680RD goat anti-mouse (925-68070,
LI-COR) and IRDye 800CW goat anti-rabbit (925-32211, LI-COR). Fluorescent signals were detected using a LI-COR Odyssey,
and images were processed using Image Studio Lite (LI-COR).
Restriction Assay and Flow Cytometry
24 h prior to infection, 1.5x105 HFFF-TERTs stably expressing shRNA constructs targeted against Sp100, HLTF or control were
plated in 24 well plates. Cells were infected with HCMV UL36-GFP at a range of low moi (0.003 – 0.3). The requisite volume of viral
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replacing themedium. 24 h after infection, cells were harvested and fixed in 4%paraformaldehyde. 30,000 events were acquiredwith
a FACSCalibur flow cytometer and analysed with FlowJo vX software. A similar approach was performed for polyclonal selected
CRISPR cell populations.
Immunofluorescence Microscopy
HFFF-TERTs were infected on coverslips with a recombinant Merlin strain with a C-terminal UL145 V5 tag, at moi 0.1 for 24 h. Cells
were then cross-linked with fixation buffer (Biolegend), permeabilised with ice-cold methanol, and blocked with Human TruStain FcX
(Biolegend). Two primary antibodies were used: rabbit anti-HLTF (ab17984, Abcam) and mouse anti-V5 (MA5-15253, Thermo).
Secondary antibodies were anti-mouse Alexa Fluor 488 (4408S, Cell Signaling) and anti-rabbit Alexa Fluor 647 (A31573, Thermo).
Cell nuclei were stained with DAPI (Cell Signaling). Fluorescence were observed using a confocal microscope (Zeiss LSM 710).
RT-qPCR
Total RNA from mock- or HCMV-infected HFFF-TERTs was extracted using an RNeasy Mini Kit (Qiagen). cDNA was synthesized
using GoScript Reverse Transcriptase (Promega), followed by RT-qPCR using Fast SYBR Green Master Mix (Applied Biosystems)
and 7500 Fast & 7500 Real-Time PCR Systems (Applied Biosystems). Primers targeting HCMV UL145 or GAPDH (as an internal
control) are shown in the Key Resources Table. The PCR program started with activation at 95C for 2 min, followed by 40 cycles
of denaturation at 95C for 5 s and annealing/extension at 60C for 30 s. Melting curve analyses were performed to verify the ampli-
fication specificity. All mock-infected samples exhibited non-singular melting curves, indicating non-specific amplification; values for
these samples were set to zero.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data Analysis
Mass spectra were processed using a Sequest-based software pipeline for quantitative proteomics, ‘‘MassPike’’, through a collab-
orative arrangement with Professor Steven Gygi’s laboratory at Harvard Medical School. MS spectra were converted to mzXML
using an extractor built upon Thermo Fisher’s RAW File Reader library (version 4.0.26). In this extractor, the standard mzxml format
has been augmented with additional custom fields that are specific to ion trap and Orbitrapmass spectrometry and essential for TMT
quantitation. These additional fields include ion injection times for each scan, Fourier Transform-derived baseline and noise values
calculated for every Orbitrap scan, isolation widths for each scan type, scan event numbers, and elapsed scan times. This software is
a component of the MassPike software platform and is licensed by Harvard Medical School.
A combined database was constructed from (a) the human Uniprot database (26th January, 2017), (b) the HCMV strain Merlin
Uniprot database, (c) all additional non-canonical human cytomegalovirus ORFs described by Stern-Ginossar et al. (Stern-Ginossar
et al., 2012), (d) a six-frame translation of HCMV strain Merlin filtered to include all potential ORFs ofR8 amino acids (delimited by
stop-stop rather than requiring ATG-stop) and (e) common contaminants such as porcine trypsin and endoproteinase LysC. ORFs
from the six-frame translation (6FT-ORFs) were named as follows: 6FT_Frame_ORFnumber_length, where Frame is numbered 1-6,
and length is the length in amino acids. The combined database was concatenated with a reverse database composed of all protein
sequences in reversed order. Searches were performed using a 20 ppm precursor ion tolerance. Fragment ion tolerance was set to
1.0 Th. TMT tags on lysine residues and peptide N termini (229.162932Da) and carbamidomethylation of cysteine residues (57.02146
Da) were set as static modifications, while oxidation of methionine residues (15.99492 Da) was set as a variable modification. For
SILAC analysis, the following variable modifications were used: heavy lysine (8.01420 Da), heavy arginine (10.00827 Da), medium
lysine (4.02511 Da), medium arginine (6.02013 Da). SILAC-only searches were performed in the same manner, omitting the TMT
static modification.
To control the fraction of erroneous protein identifications, a target-decoy strategy was employed (Huttlin et al., 2010). Peptide
spectral matches (PSMs) were filtered to an initial peptide-level false discovery rate (FDR) of 1% with subsequent filtering to attain
a final protein-level FDR of 1%. PSM filtering was performed using a linear discriminant analysis, as described previously (Huttlin
et al., 2010). This distinguishes correct from incorrect peptide IDs in a manner analogous to the widely used Percolator algorithm
(https://noble.gs.washington.edu/proj/percolator/), though employing a distinct machine learning algorithm. The following parame-
ters were considered: XCorr, DCn, missed cleavages, peptide length, charge state, and precursor mass accuracy.
Protein assembly was guided by principles of parsimony to produce the smallest set of proteins necessary to account for all
observed peptides (algorithm described in Huttlin et al., 2010). Where all PSMs from a given HCMV protein could be explained either
by a canonical gene or non-canonical ORF, the canonical gene was picked in preference.
In eleven cases, PSMs assigned to a non-canonical or 6FT-ORF were a mixture of peptides from the canonical protein and the
ORF. This most commonly occurred where the ORF was a 5’-terminal extension of the canonical protein (thus meaning that the
smallest set of proteins necessary to account for all observed peptides included the ORFs alone). In these cases, the peptides
corresponding to the canonical protein were separated from those unique to the ORF, generating two separate entries. In a single
case, PSM were assigned to the 6FT-ORF 6FT_6_ORF1202_676aa, which is a 5’-terminal extension of the non-canonical ORF
ORFL147C. The principles described above were used to separate these two ORFs.
Proteins were quantified by summing TMT reporter ion counts across all matching peptide-spectral matches using ’’MassPike’’, as
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127c, 128n, 128c, 129n, 129c, 130n, 130c, 131n, 131c) was scanned for ions, and the maximum intensity nearest to the theoretical
m/z was used. The primary determinant of quantitation quality is the number of TMT reporter ions detected in each MS3 spectrum,
which is directly proportional to the signal-to-noise (S:N) ratio observed for each ion. Conservatively, every individual peptide used for
quantitation was required to contribute sufficient TMT reporter ions (minimumof500 per spectrum) so that each on its own could be
expected to provide a representative picture of relative protein abundance (McAlister et al., 2014). An isolation specificity filter with a
cutoff of 50% was additionally employed to minimise peptide co-isolation (McAlister et al., 2014). Peptide-spectral matches with
poor quality MS3 spectra (more than 9 TMT channels missing and/or a combined S:N ratio of less than 100 across all TMT reporter
ions) or noMS3 spectra at all were excluded from quantitation. Peptidesmeeting the stated criteria for reliable quantitation were then
summed by parent protein, in effect weighting the contributions of individual peptides to the total protein signal based on their
individual TMT reporter ion yields. Protein quantitation values were exported for further analysis in Excel.
For protein quantitation, reverse and contaminant proteins were removed, then each reporter ion channel was summed across all
quantified proteins and normalised assuming equal protein loading across all channels. For further analysis and display in Figures,
fractional TMT signals were used (i.e. reporting the fraction of maximal signal observed for each protein in each TMT channel, rather
than the absolute normalized signal intensity). This effectively corrected for differences in the numbers of peptides observed per
protein.
For pulsed SILAC experiments, after protein assembly, medium-labelled peptides (measuring protein degradation), and heavy-
labelled peptides (measuring protein synthesis) were extracted then re-assembled into medium- and heavy-labelled proteins using
an in-house script written in Python (version 2.7). Protein normalisation across reporter ion channels again assumed equal protein
loading (i.e. for each TMT channel, the summed protein S:N including all medium- and heavy-labelled proteins was the same).
For each protein, values were further normalised to the time 0 sample for display in Figures. For all TMT or pSILAC experiments,
normalised S:N values are presented in Table S1 (‘Data’ worksheet). For SILAC immunoprecipitations, normalisation assumed equal
protein loading across all samples.
Although peptides were assigned appropriately to HLA-A alleles, it was not possible confidently to assign peptides to only two
HLA-B or HLA-C alleles. For the 5 HLA-B or HLA-C alleles that had the greatest summed number of peptides across all experiments,
signal:noise values were further summed to give a single combined result for HLA-B or HLA-C.
Hierarchical centroid clustering based on uncentered Pearson correlation, and k-means clustering were performed using Cluster
3.0 (Stanford University) and visualised using Java Treeview (http://jtreeview.sourceforge.net) unless otherwise noted. Multiple
sequence alignment was performed using Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/) provided by EMBL-EBI.
Comparative Data Analysis Using Proteome Discoverer
To compare data generated using ‘‘MassPike’’ with another platform, we re-analysed raw MS files for the 12, 18 and 24 h inhibitor
experiments using Proteome Discoverer 2.2 (Thermo Fisher Scientific) (Figure S7). Data were searched in Sequest against an
identical combined database to that described in the ‘‘Data analysis’’ section. Searches were performed using a 20 ppm precursor
ion tolerance and fragmentmass tolerance of 0.5 Da. TMT tags on lysine residues and peptide N termini and carbamidomethylation of
cysteine residues were set as static modifications, and oxidation of methionine residues was set as a variable modification.
Percolator (https://noble.gs.washington.edu/proj/percolator/) was used to control the fraction of erroneous protein identifications,
with a peptide false discovery rate of 1% for ‘high’ confidence PSMs and 5% for ‘medium’ confidence PSMs. Proteins were subse-
quently filtered to attain a final protein-level FDR of 1% (‘strict’ criteria) or 5% (‘relaxed’ criteria). Protein assembly was guided by
principles of parsimony. MS3 spectra were used for reporter ion based quantitation with a most intense centroid tolerance of
20 ppm. An average reporter S:N value of 10 was used for quantitation and an isolation specificity filter with a cutoff of 50% was
employed to minimize peptide co-isolation. Peptides meeting these criteria were summed by parent protein, and quantitation values
were exported for further analysis in Excel. For protein quantitation, reverse and contaminant proteins were removed, and then each
reporter ion channel was summed across all quantified proteins and normalised assuming equal protein loading across all channels.
Histone Proteomic Ruler
The cellular concentrations of viral proteins in whole cell lysates from the 6 h pSILAC experiment (Figure 7A) were calculated using a
‘proteomic ruler’ approach implemented in the Perseus plugin (http://www.coxdocs.org/doku.php?id=perseus:user:plugins:
proteomicruler:estimatecopynumbers) (Wisniewski et al., 2014). This used the mass spectrometry signal of histones from the 6 h
HCMV-infected sample to scale other proteins of unknown concentration from the same sample. Briefly, intensity values that had
been normalised assuming equal protein loading across all samples were imported into Perseus. Molecular weights of all human
and canonical HCMV proteins were obtained from Uniprot. Predicted masses of non-canonical HCMV ORFs and six-frame transla-
tions were obtained using an online molecular weight calculator (https://www.bioinformatics.org/sms/prot_mw.html). Scaling was
using the histone proteomic ruler, assuming a ploidy of 2.
RNAseq Data Analysis
RNA samples were collected in biological triplicate. Reads were aligned to the Human genome (hg19) and HCMV Merlin
strain genome (NC_006273.2) using the aligner STAR version 2.5.2b (http://code.google.com/p/rna-star/). Read counts for each
gene/transcript were determined using HTSeq version 0.6.1 (https://pypi.org/project/HTSeq/) with the following optional
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per run; HCMV reads were not included in this normalisation since by 72 h HCMV accounted for a significant proportion of all reads
(0h: <0.01%, 24 h: 4.7-5.8%; 72 h: 41.8-42.3% HCMV reads). For HCMV, reads for each barcode were normalised assuming equal
total reads (human plus HCMV) per sequencing run. Reads per Kilobase per Million (RPKM) values were calculated in Excel and
further normalised to 1. Mean and standard error of the mean (SEM) values are shown in Table S1 and Figures 3, 5, S1–S3, and
S5. Although data for HCMV reads is included in Table S1, this analysis may be confounded by overlapping viral transcripts. For Fig-
ure 5F, as UL145 transcripts do not overlap with transcripts from the neighboring UL144 and UL146 genes, the sequences detected
by RNAseq could be reliably ascribed to UL145 (Sun et al., 2007).
Statistical Analysis
The exact value of nwithin figures is indicated in the respective figure legends, and refers to the number of biological replicates. Blind-
ing or sample-size estimation was not appropriate for this study. There were no inclusion criteria and no data was excluded.
Figures 1, S2, S3, and S5. The inhibitor experiments were performed in single replicates at each of 12, 18 and 24 h after infection.
Protein ‘rescue ratios’ were approximately normally distributed (Figure S1B). The method of significance A was used to estimate the
p-value that each ratio was significantly different to 1 (Cox and Mann, 2008). Values were calculated and corrected for multiple
hypothesis testing using the method of Benjamini-Hochberg in Perseus version 1.5.1.6 (Cox and Mann, 2008). A corrected
p-value <0.01 was considered statistically significant.
Figures 2, S2, S3, and S5. The pSILAC experiments were performed in single replicates at each of 6 and 18 h after infection. With
respect to protein concentration, protein degradation typically follows first order kinetics whereas protein synthesis is a zero-order
process. For pSILAC data, the rate of protein decline in mock- and HCMV-infected samples was therefore estimated using exponen-
tial regression in Excel and the formula [protein] (t) = eKdeg x t where Kdeg is the rate constant for degradation, and should be negative
for degraded proteins. A degradation ratio was calculated by rdeg = KdegHCMV/Kdegmock. In cases where this ratio could not be
calculated because Kdegmock was greater than 0, a fold change (FCHCMV) in protein abundance in the HCMV-infected sample at
6 h (6 h pSILAC experiment) or 18 h (18 h pSILAC experiment) was instead used, defined by FCHCMV = 1/e
Kdeg(HCMV) x t. Protein
half-life was estimated by t1/2 = ln(0.5)/Kdeg. The corresponding rates of protein synthesis were estimated using linear regression
in Excel and the formula [protein] (t) = Ksyn x t where Ksyn is the rate constant for synthesis. We determined if KdegHCMV was signif-
icantly different to Kdegmock, and if KsynHCMV was significantly different to Ksynmock using an in-house script written in R (version
3.4.2). For each peptide, the difference in paired normalised signal:noise values at each of the five measured time points was calcu-
lated. A simple linear regressionmodel without an intercept was fitted to paired difference data from all peptides for each protein, and
a p-value calculated for the null hypothesis of the slope being zero. All p-values were corrected for multiple hypothesis testing using
the method of Benjamini-Hochberg (Benjamini and Hochberg, 1995). A Benjamini-Hochberg-corrected p-value <0.05 was consid-
ered statistically significant.
For Figure 2E, all viral proteins were included where KsynHCMV was significantly higher than Ksynmock at p<0.05. As the measure-
ment of viral proteins in mock-infected samples was at the level of noise, the value of the ratio KsynHCMV/Ksynmock was not consid-
ered. All human proteins were included with KsynHCMV/Ksynmock >3 and p<0.05.
Figures 3, S2, S3, and S5. TheWCL2 experiment was performed using single replicates collected atmultiple time points as detailed
in the figure, apart from the mock sample which was collected in biological duplicate (Weekes et al., 2014). The RNAseq experiment
was performed in biological triplicate at 0, 24 and 72 h after infection. Mean and SEMwere calculated for normalised RPKM values for
each time point 0, 24, 72 h (n=3). Fold change at 24h was calculated from mean RPKM(24 h)/mean RPKM(0h). A similar value was
calculated for 72 h data. A Benjamini-Hochberg corrected student’s t-test was used to estimate the p-value for the hypothesis that a
given transcript was expressed significantly differently at 24 or 72 h compared to mock infection. For protein expression from
experiment WCL2, fold change at time t was calculated from S:N (t) / S:N (0h). p-values that a given protein was expressed signif-
icantly differently at 24 or 72 h compared to mock infection were estimated using Benjamini-Hochberg-corrected significance
A values (Cox and Mann, 2008). XLStat (Addinsoft) was used to calculate the summed distance of each protein from its cluster
centroid (Figure S4), and k-means clustering was performed in Cluster 3.0 (Stanford University).
Figures 5 and S6. The block deletion screens were conducted in partial biological duplicate as detailed below. Two block viral
gene-deletion screens Block1 and Block2 were conducted. For each protein in each screen, a mean (m) and standard deviation
(s) of all normalised S:N values was calculated. In each case, themaximum (x) value was omitted. For example, for HLTF in Figure 5A,
m and swere calculated using values for wt1, wt2, RL10-UL1, RL11-UL11, UL2-UL11, US1-US11, US18-US22, US29-US34A but not
the maximum UL/b’. The formula z = (x – m)/s was then applied to calculate a z-score. Fold change (FC) compared to wild-type (wt)
infection was calculated from normalised S:N values using FC = x/wt1. Because of the limits of multiplexing with TMT, block deletion
viruses AD169 (UL/b’), DUS27-28, DUL13-20, DUS12-17 were only examined in a single screen. All other block deletion viruses were
examined in both screens. For each experiment, a given protein was initially assigned to the block corresponding to the TMT channel
with the maximum S:N. To combine results to assign an overall block to each protein:
For Proteins Assigned to Blocks Studied in Both Screens
If the protein was quantified in both screens and assigned to the same block, z-scores and fold changeswere averaged. For example,
HLA-A11 was assigned to the US1-US11 block in both screens (Figure 5A), so the average of the two z-scores (17.1 and 112.6) was
used to give a combined z=64.8. If the protein was only quantified in one of the two screens, the block assignment, z-score and fold
change from that screen were used (for example, for CXADR, Figure S6B). Otherwise, it was not considered possible to assign an
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For Proteins Assigned to One of the UL/b’, US27-28, UL13-20, US12-17 Blocks, Which Were Only Examined in 1/2
Screens
If the protein was quantified in both screens, and assigned to one of UL/b’, US27-28, UL13-20, US12-17 in 1/2 screens, the assign-
ment in the other screen would have been different as these blocks were not examined in duplicate. To assign an overall block, the
following rule was employed: if the z-score of the block assignment in one screen was at least 3.5 higher than the z-score of the block
assignment from the other screen, the z-score and fold change from the former screen were used. For example, ABCC1 was
assigned to the UL/b’ block in Block1 (z=5.44, FC=2.23) and the US29-US34A block in Block2 (z=1.87, FC=1.16). Since the difference
in z-scores was 3.57, the data for Block1 was used.
To confidently assign proteins to viral blocks, stringent criteria were used with a combined z-score of >6 and FC>2 or sensitive
criteria with a combined z-score of >5 and FC>1.5. ABCC1 was therefore assigned to the UL/b’ block by sensitive criteria, in keeping
with our previous data (Weekes et al., 2013).
Figure 6. SILAC immunoprecipitations shown in Figures 6B and 6E were performed in single replicates. p-values were estimated
using Benjamini-Hochberg-corrected significance A from Perseus version 1.5.1.6 (Cox and Mann, 2008).
Figure 7. All experiments in this figure were performed in biological triplicate. p-values were estimated using a 2-way ANOVA (B) or
a two-tailed t-test (D, E, F).
Pathway Analysis
The Database for Annotation, Visualisation and Integrated Discovery (DAVID) was used to determine pathway enrichment (Huang da
et al., 2009). A given cluster was always searched against a background of all proteins quantified within the relevant experiment. For
Figure 4A, DAVID analysis examined all proteins identified as degraded at any of the three time points for the inhibitor screen, proteins
degraded in either of the two time courses for the pSILAC screen, or proteins degraded at either time point for the RNA/protein
screen.
DATA AND SOFTWARE AVAILABILITY
Unprocessed peptide data files for Figures 1, 2, 3, and 5 have been deposited toMendeley Data and are available at http://dx.doi.org/
10.17632/zkgmjzrcyk.1. These files include details of peptide sequence, redundancy, protein assignment raw unprocessed TMT
reporter intensities and isolation specificity. RNAseq metadata, processed data and FASTQ files can be accessed via
GEO: GSE111036. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (http://
www.proteomexchange.org/) via the partner repository PRIDE: PXD009945.Cell Host & Microbe 24, 447–460.e1–e11, September 12, 2018 e11
